RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 3/22 #TumorBoardTuesday #GI23 #CRCAwareness
👩🏻‍🏫Mini tweetorial 1👨🏻‍🏫

↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp

↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 3/22 #TumorBoardTuesday #GI23 #CRCAwareness
👩🏻‍🏫Mini tweetorial 1👨🏻‍🏫

↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp

↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 3/22 #TumorBoardTuesday #GI23 #CRCAwareness
👩🏻‍🏫Mini tweetorial 1👨🏻‍🏫

↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp

↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 3/22 #TumorBoardTuesday #GI23 #CRCAwareness
👩🏻‍🏫Mini tweetorial 1👨🏻‍🏫

↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp

↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 3/22 #TumorBoardTuesday #GI23 #CRCAwareness
👩🏻‍🏫Mini tweetorial 1👨🏻‍🏫

↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp

↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 3/22 #TumorBoardTuesday #GI23 #CRCAwareness
👩🏻‍🏫Mini tweetorial 1👨🏻‍🏫

↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp

↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO

RT @MPishvaian
#TumorBoardTuesday #GI23
✅Dr. Moehler presented a Ph3 trial demonstrating that chemo➕tiselizumab⬆️mOS over chemo alone in gastric/GE Jx Cancer
➡️mOS was improved by 4.5 months‼️

🤔BUT....how are you going to choose
🤷Chemo + nivo❓
or
🤷Chemo + tisle❓

RT @MPishvaian
#TumorBoardTuesday #GI23
A lot of strong feelings about Zev Wainberg's🖥️demonstrating NALIRIFOX⬆️OS compared to gem-nab-pac
➡️11.1 mos vs. 9.2 mos
🤮More GI tox with NALIRIFOX
😷More heme tox with gem-nab-pac

🤔What are your thoughts 1 week later - will you use NALIRIFOX❓

RT @MPishvaian
#TumorBoardTuesday #GI23
@rachnatshroff made the best of a negative trial in her🖥️
➡️This was an important trial because many of us have been using GAC in anticipation of a better outcome
🤷At least we no know not to use it anymore

RT @MPishvaian
#TumorBoardTuesday #GI23
I was🤔more about the presentation by @DrElkhoueiry
➡️Take a look👁️at the survival curve for gem-cis-bev-atezo
➡️>60% of the patients are alive after 12 months
👉Is that going to be maintained❓
👉That would be truly a game changer‼️

RT @pashtoonkasi
👇🏾A lot of great data & discussion here on this🧵by @MPishvaian @TumorBoardTues. #GI23 @ASCO

Additionally, intriguing insights with practical implications on🩸#ctDNA #LiquidBiopsies: data on kinetics 📉, post-op cfDNA🆚ctDNA interactions/timing, & data in anal cancer. @OncoAlert https://twitter.com/mpishvaian/status/1620588991828590592

RT @JohnEbbenMDPhD
From new validation for ✅Claudin 18.2 targeting in #gastricadenocarcinoma/#GEJ to ✅IO responses in MSS #colorectalcancer, #GI23 was full of big updates. Join #TumorBoardTuesday as @MPishvaian takes us through a recap of some of the big news coming out of GI ASCO. https://twitter.com/MPishvaian/status/1620588991828590592

RT @TumorBoardTues
#TumorBoardTuesday
🧑‍🏫Now that all the incredible data from #GI23 has settled into our🧠 @JohnEbbenMDPhD & @MPishvaian will give their take on the most impactful🗣️

📢Join us at 8PM🕗EST, Tuesday, 01.31.23 and weigh in with your💭

👉And tells us where you are in your🩺journey❓

RT @MPishvaian
#TumorBoardTuesday #GI23
And last but not least🥁
An abstract only🖥️by Jin, et al
➡️They describe the results of a trial showing a 67% ORR to IO for tumors with POLE/POLD1 exonuc domain muts

Congratulations for the VERY hard work by all the presenters/submitters at #GI23 👏

RT @MPishvaian
#TumorBoardTuesday #GI23
New🎯alert🚨(sort of)
✅Yamamoto, et al presented data in MDM2 amplified cholangioCa patients treated with the
MDM2⛔️BI 907828
➡️50% ORR (5/10 patients)‼️
➡️Durable outcomes with some patients on Tx for > 6months😀

👉More patients to be enrolled

RT @MPishvaian
#TumorBoardTuesday #GI23
All the HER2🎯💊trials in #colorectalcancer are single arm studies
🤔So is HER2🎯💊= to chemo❓
Raghav, et al @MDAndersonNews 🖥️a trial of Tras/Pertuz vs. CETIRI
➡️Simlar ORR (slightly⬆️for TP) & mPFS‼️
✅So HER2🎯💊is at least as good, with much less🤢

RT @MPishvaian
#TumorBoardTuesday #GI23
The last trial that I was🙏for was dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mut mCRC🖥️by Chen, et al
➡️This4⃣drug combo only resulted in a mPFS of 7.5 mos, and ORR of 30% - which is very similar to encorafenib + cetux alone😔

RT @MPishvaian
#TumorBoardTuesday #GI23
🤔Many of us have asked how do we⬆️IO efficacy❓
✅Seligmann, et al ran a nice study to see if local Tx ⬆️ORR
👉23 HCC pts were Txed w/ SBRT or RFA and received durva➕treme concurrently
👉But the ORR was 0%

I really thought this study was promising😔

RT @MPishvaian
#TumorBoardTuesday #GI23
🫤There were a few WELL DONE studies with results that were unexpectedly⛔️
➡️@DrAngelaLamarca, et al evaluated #cholangiocarcinoma patients treated with platinum therapy
👉There was NOT any difference in mOS when comparing DDR-WT vs. DDR-mut tumors😔

RT @MPishvaian
#TumorBoardTuesday #GI23
@KoheiShitara 's presentation of FOLFOX+/-zolbetuximab in Gastric/GEJ jxn Ca wasn't just practice changing:
➡️~3 mo⬆️in mOS, achieving an 18.2 month mOS
✅A new standard of care👏

But it also validated a new🎯in Claudin18.2
👍More Claudin 18.2🎯💊coming